(Q44705817)

5 December 2017

Correlation of lamotrigine concentrations between serum and saliva (English)

1 reference

5 December 2017

1 reference

1 reference

Melody Ryan

1

1 reference

5 December 2017

Shellee A Grim

2

1 reference

5 December 2017

Michael V Miles

3

1 reference

5 December 2017

Peter H Tang

4

1 reference

5 December 2017

Toufic A Fakhoury

5

1 reference

5 December 2017

Richard H Strawsburg

6

1 reference

5 December 2017

Ton J deGrauw

7

1 reference

5 December 2017

Robert J Baumann

8

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

1 reference

5 December 2017

23

1 reference

5 December 2017

12

1 reference

5 December 2017

1550-1557

1 reference

Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide

5 December 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Is there a role for therapeutic drug monitoring of new anticonvulsants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Therapeutic drug monitoring--antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Population pharmacokinetics of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Clinical pharmacokinetics of anticonvulsants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Lamotrigine for the treatment of epilepsy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Efficacy, tolerability, and kinetics of lamotrigine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Lack of an effect of topiramate on lamotrigine serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Use of saliva in monitoring carbamazepine medication in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Value of saliva samples in monitoring carbamazepine concentrations in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Use of saliva for monitoring oxcarbazepine therapy in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Saliva and serum concentration of lamotrigine in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

The Efficacy of Lamotrigine in Children and Adolescents with Refractory Generalized Epilepsy: A Randomized, Double-Blind, Crossover Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

Fallacious results from measuring salivary carbamazepine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.15.1550.31957

10.1592/PHCO.23.15.1550.31957

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference